TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01070199

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: liquid to liquid
Description: • One test session will involve presentation of a glass of clear cherry-flavored unthickened beverage (Kool-Aid, Kraft Foods Inc., White Plains, NY). This session will be referred to as the Liquid to Liquid session as the participants will be consuming a liquid and be told that the consistency in their stomach will be a liquid.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: liquid to solid
Description: This session involves a solution of calcium chloride and a solution of sodium alginate. The participant will be instructed to pour the cherry-flavored beverage/alginate solution into the calcium chloride. The result is a solid mass. They are allowed to examine the solution to confirm the solid texture and consistency.Participants will be told that this same reaction will occur in their stomach when the session's beverage is consumed due to the effect of gastric acid on the solution. But, the participant will be consuming the same cherry-flavored beverage as in the 1st session. Thus, they will believe that their GI tract will be challenged with a solid mass, but in reality, the challenge is the same (i.e., liquid).Therefore, the only difference between the test sessions is expectation.
Study: NCT04306211

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SuperNO2VA
Description: SUPERNO2VA is nasal PAP device for oxygen delivery
Study: NCT00595309

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IC51
Description: IC51, 6 mcg, intramuscular (i.m.) booster vaccination 15 months after the primary immunization
Study: NCT06035835

Intervention type: COMBINATION_PRODUCT
Intervention: Lacticaseibacillus rhamnosus
Description: Administration Lacticaseibacillus rhamnosus (L. Rhamnosus) ATCC 53103 (109 UFC/day)

Intervention type: COMBINATION_PRODUCT
Intervention: Lactobacillus acidophilus + Bifidobacterium bifidum
Description: Administration Lactobacillus acidophilus (L. acidophilus) ATCC 4356 (109 UFC/12 h)+Bifidobacterium bifidum (B. bifidum) ATCC 15696 (109 UFC/12 h)
Study: NCT03214783

Intervention type: OTHER
Intervention: Facial characteristics
Description: The exposures are facial characteristics which differ significantly in exposure rates between coronary artery disease (CAD) group and no CAD group.

Intervention type: OTHER
Intervention: Facial characteristics
Description: The exposures are facial characteristics which differ significantly in exposure rates between coronary artery disease (CAD) group and no CAD group.
Study: NCT04728009

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Longan and lingzhi mushroom syrup
Description: Fresh fruit pulps of longan were stewed in hot water until they softened. No sugar and additives were added. The pulps were removed by filtration in order to obtain concentrated longan juice. After that, spray-dried powder of lingzhi mushroom extract was dissolved in water in the ratio of 1:2. To make the finished product, 99 g of longan juice was mixed with 1 g of the lingzhi extract in water. The sugar content of the syrup was 77 degrees Brix.
Study: NCT03309865

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: semi-vegetarian diet
Description: semi-vegetarian dietary intervention: Duration of Therapy: 14 weeks;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab Injection
Description: vedolizumab (300mg) IV infusions at week 0, 2, 6, 14; Duration of Therapy: 14 weeks
Study: NCT00526227

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Secura ICD
Description: Secura Implantable Cardioverter Defibrillator (ICD) will be implanted
Study: NCT01070199

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: solid to liquid
Description: • This session will involve the same dense gelatin cubes previously described, but participants will be told that the solid cubes will turn to liquid when they come into contact with the acid in their stomach. This trial will be known as Solid to Liquid. A demonstration of the Solid to Solid and Solid to Liquid phases will be shown to the participant before they consume the load. Both phases exhibited by placing two cubes into separate containers filled with similar looking clear liquids. The Solid to Solid phase container will contain cold water so the cube stays in solid form. The Solid to Liquid phase container will contain hot water that will quickly dissolve the cube into a liquid form.
Study: NCT02915133

Intervention type: PROCEDURE
Intervention: macular buckling surgery
Description: Participants with high myopia foveoschisis are scheduled to macular buckling (MB) surgery.
Study: NCT01070199

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: solid to solid
Description: Participants will be presented with dense gelatin cubes. These 1 x 1 x 1 cubes will have a solid appearance and require mastication, but is isocaloric to the beverage. However, after mastication and gastric processing, the solid rapidly breaks down into a clear fluid.However, participants will be informed that the cubes will remain the same solid consistency in their stomach. The masticatory process and stimulus form will be standardized through the use of a metronome. Participants will be required to chew the solid cube at a fixed rate prior to swallowing. Thus, adding to the cognitive impression that they are eating a solid when essentially the GI challenge will be similar to the beverage.
Study: NCT02838186

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: retroflexion
Description: examination of the right colon with scope retroflexion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: forward view
Description: examination of the right colon in forward view
Study: NCT02486263

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study Arm - acid suppression plus feeding bundle
Description: * Omeprazole 0.5-1.5 milligrams/kilogram/dose twice a day (BID)~* Total fluid volume restriction (120-140 milliliters/kilogram/day)~* Feeding duration over 30 minutes~* Infant feeds with right side down~* Infant is placed on back following feeds

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional arm - acid suppression only
Description: -Omeprazole 0.5-1.5 milligrams/kilogram/dose twice a day (BID)
Study: NCT03163277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: emtricitabine, darunavir/cobicistat, maraviroc
Description: Treatment change
Study: NCT04832633

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Different contrast media injection methods
Description: Different contrast media injection methods
Study: NCT02408523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasosamide Oral Solution
Description: * Active Substance: Lacosamide~* Pharmaceutical Form: Oral Solution~* Concentration: 10 mg/ml~* Route of Administration: Oral use
Study: NCT04832633

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Different contrast media injection methods
Description: Different contrast media injection methods

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Different contrast media injection methods
Description: Different contrast media injection methods
Study: NCT02408523

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablet
Description: * Active Substance: Placebo~* Pharmaceutical Form: Film-coated Tablet~* Concentration: 50 mg~* Route of Administration: Oral use
Study: NCT03161184

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SUSTAIN Smartphone training of CHW (SP+)
Description: Intervention (Smart phone assisted): During prenatal household visits, the smart phone based application guides CHW through electronic decision tree protocols, directing them to specific health/nutrition counseling topics and messages based on each woman's gestational age, and her answers to a specific series of diagnostic questions. Based on the client's gestational age, the tool directs CHW to lessons in an accompanying photo book, and reminds them to counsel on the importance of accessing timed and targeted maternal health services at health facilities. The application also assists CHW to identify danger signs during pregnancy, flags clients who require immediate referral to health facilities, and reminds CHW to follow-up with clients who were previously referred to clinics.
Study: NCT02408523

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Solution
Description: * Active Substance: Placebo~* Pharmaceutical Form: Oral Solution~* Concentration: 10 mg/ml~* Route of Administration: Oral use
Study: NCT03137628

Intervention type: OTHER
Intervention: colectomy, GA and MV
Description: general anesthesia protocol: anesthesia induction (midazolam 0.1mg/kg, sufentanil 0.5ug/kg, etomidate 0.3mg/kg, cisatracurium 0.2mg/kg); anesthesia maintenance \[sevoflurane 1.5-3%, cisatracurium 0.1mg/kg/h, sufentanil is supplemented during the entire surgical procedure according to patients' anesthetic situation, dexmedetomidine（used conditionally）0.4ug/kg/h\].~mechanical ventilation protocol: tidal volume 6-8 ml/kg, positive end-expiratory pressure 5 cmH2O, oxygen concentration 40%; respiratory rate 10-15/min, inspiratory/expiratory ratio 1:1.5.
Study: NCT00480389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Starting dose: 400 mg (2x200mg tablets) BID (total= 800mg/day) taken orally. The dose can be adjusted as per investigator if required due to toxicity (ex. 200mg BID, 200mg QD). Study drug is taken for 12 weeks preoperatively. Patients restart on study drug 6 weeks postoperatively and continue until progression or unacceptable toxicity occurs.
Study: NCT03161184

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SUSTAIN Paperbased training of CHW (SOC)
Description: SUSTAIN Paperbased training of CHW (SOC): During prenatal household visits, the CHW asks a specific series of diagnostic questions based on the client's gestational age, offers counsel on the importance of accessing appropriate maternal health services at health facilities and uses lessons in an accompanying photo book to deliver messages on a variety of maternal and newborn health and nutrition topics. CHW are trained to identify danger signs during pregnancy, flag clients who require immediate referral to health facilities, and follow-up with clients who were previously referred to clinics.
Study: NCT02888730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobramycin nebulized nasally
Description: Two sonic nebulizations per day will be realized by patients: morning and evening during 15 days. There should be a maximum of 12 hours between the 2 doses but shall not be less than 6 hours. The dosage should not be adjusted to body weight. All patients will receive one ampoule of tobramycin twice a dayAmpoules of tobramycin are filled by 5 ml containing 300 mg of tobramycin and 11.25 mg of sodium chloride. Bulb should be employed in nebulizer and administered by the inhalation route approximately 15 minutes to complete.Antibiotic retained for the study, tobramycin is manufactured by the Pharmacie à Usage Interne of the Henri Mondor Hospital. The study's product will be prepared with Base Tobramycin and excipients in accordance with TOBI's composition.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Physiologic serum nebulized nasally
Description: Two sonic nebulizations per day will be realized by patients: morning and evening during 15 days. There should be a maximum of 12 hours between the 2 doses but shall not be less than 6 hours. The dosage should not be adjusted to body weight. All patients will receive one ampoule of placebo (Nacl 0.9%) twice a day.Ampoules of placebo are filled by 5 ml containing of sodium chloride. Bulb should be employed in nebulizer and administered by the inhalation route approximately 15 minutes to complete. Placebo for the study is manufactured by the Pharmacie à Usage Interne of the Henri Mondor Hospital. Patients in placebo arm will receive 5ml of sodium chloride with the same color (light yellow transparent) as tobramycin
Study: NCT03140787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal Spray of Lidocaine HCL
Description: This spray consists of lidocaine hydrochloride-epinephrine hydrochloride
Study: NCT03161184

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SUSTAIN Paperbased training of CHW (SOC)
Description: SUSTAIN Paperbased training of CHW (SOC): During prenatal household visits, the CHW asks a specific series of diagnostic questions based on the client's gestational age, offers counsel on the importance of accessing appropriate maternal health services at health facilities and uses lessons in an accompanying photo book to deliver messages on a variety of maternal and newborn health and nutrition topics. CHW are trained to identify danger signs during pregnancy, flag clients who require immediate referral to health facilities, and follow-up with clients who were previously referred to clinics.
Study: NCT03935945

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Feedback Intervention
Description: Participants in the intervention group will receive a computerized personalized feedback intervention (PFI) lasting approximately 20-30 minutes. PFI highlights discrepancies between one's own drinking and typical drinking; reframes use in terms of personal, social, financial, and health consequences; and, offers strategies for reducing alcohol use. The feedback is non-confrontational in tone, seeks to increase motivation to reduce drinking and is based on the information provided during the baseline assessment
Study: NCT01659437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin Extended Release
Description: oral administration of Clarithromycin extended release

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Streptomycin intramuscular injection
Description: daily intramuscular drug injection
Study: NCT00781612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel will be administered as per local prescribing information.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered as per local prescribing information.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Pertuzumab will be administered intravenously at a dose of 420 milligrams (mg) no more frequently than every 3 weeks (Q3W) (or as directed in the parent study protocol if less than Q3W).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab will be administered as per local prescribing information.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Emtansine
Description: Trastuzumab emtansine will be administered as intravenous (IV) infusion. Participants on weekly dosing schedule of trastuzumab emtansine in parent study, may switch to Q3W schedule as per the clinical judgment of the investigator. The starting dose of Q3W schedule must not exceed 3.6 milligrams per kilograms (mg/kg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered at a dose of 1200 mg by IV infusion every three weeks (Q3W)
Study: NCT03140787

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infiltration injection of Lidocaine HCL
Description: This is the ordinary method of establishing anesthesia for patients undergoing dental treatment for caries.
Study: NCT03878212

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mHealth application with interactivity
Description: a mHealth device with interactivity with nurse case manager

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mHealth application
Description: a mHealth device
Study: NCT02995863

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rigid Rocker Sole Footwear

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Footwear
Study: NCT02727972

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive Testing
Description: Verbal assessments as well as computer testing.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: Anatomical MRIs will be performed on a Siemens 3T Trio at Yale. MR acquisition will be a Sag 3D magnetization-prepared rapid gradient-echo (MPRAGE) sequence with 3.34 ms echo time, 2,500 ms repetition time, 1,000 ms inversion time, 7 degree flip angle, and 180 Hz/pixel bandwidth. The image dimensions will be 256 x 256 x 176 and pixel size 0.98 x 0.98 x 1.0 mm. Resting state MRIs will also be obtained as follows: We will be doing 2 six minute scans with subjects in the scanner, eyes open, fixating a cross. TR = 3 secs 45 slices x 3 mm slice thickness = 13.5 cm. In plane resolution = 3 x 3 mm, slice acquisition order = ascending.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: PET
Description: High Resolution Research Tomograph (HRRT), the highest resolution human brain scanner available, or HR+ will be used to image subjects. Vital signs (blood pressure, pulse, respiration) will be obtained before and after radiotracer administration. An antecubital venous catheter will be used for IV administration of the radiotracer and for venous blood sampling. A radial artery catheter will be inserted by an experienced physician before the PET scan. At the beginning of each scan, the subject's head will be immobilized and a 6 minute transmission scan using an orbiting 137Cs (HRRT) or 68GE (HR+) point-source is obtained and used for attenuation correction. PET scans will be acquired using bolus or bolus plus constant infusion administration of FPEB or ABP688.
Study: NCT02146352

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AXIOS Stent with Electrocautery Enhanced Delivery System
Description: Endoscopy with ultrasonography to implant AXIOS stent using electrocautery enhanced delivery system to allow drainage of pancreatic pseudocyst. Removal of AXIOS stent after 30 or 60 days.
Study: NCT03660566

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Test - Implant with L-PRF
Description: The patient's blood will be collected and the tubes (4) will be inserted into a tabletop centrifuge (Kasvi). Using a 2500rpm for 12 minutes protocol, the leucocyte- and platelet-rich fibrin clot will be prepared using a kit consisting of a perforated metal box where the clots will be positioned and covered by a metal plaque. The pressure exerted on the clot will lead to the formation of L-PRF membranes, which will be used to cover the ridge after placement of the implant. Then, the flap will be sutured.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control - Implant without L-PRF
Description: Single implant installation surgery in maxillary esthetic area.
Study: NCT00935766

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3
Description: Subjects meeting eligibility criteria will be randomized to receive a supply of omega-3-acid ethyl esters or placebo, and instructed to take 4 capsules daily. A 3-month supply of study drug will be given following randomization and at 3, 6, and 9 months. Subjects will be asked to bring unused supplies to each quarterly visit for ascertainment of adherence.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04126876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tilsotolimod
Description: Intradermal, single injection of 1 ml (8 mg) Tilsotolimod (IMO-2125) at the primary melanoma excision site, one week prior to sentinel node biopsy (SNB).
Study: NCT02252965

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin IR
Description: Subjects will receive Metformin Immediate Release (IR) tablets, orally once daily at a dose of 500 milligram (mg) for 1 week, and then dose will increase with increments of 500 mg every week in first 2 weeks to 1500 mg. After that dose will increase up to maximum dose of 2000 mg for the next 2 weeks and will be maintained at 2000 mg until Week 16.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin XR
Description: Subjects will receive Metformin Extended Release (XR) tablets, orally once daily at a dose of 500 mg for 1 week, and then dose will increase with increments of 500 mg every week in first 2 weeks to 1500 mg. After that dose will increase up to maximum dose of 2000 mg for the next 2 weeks and will be maintained at 2000 mg until Week 16.
Study: NCT01705093

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: flavonoid-rich freeze-dried strawberry powder
Description: 50g of flavonoid-rich freeze-dried strawberry powder

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: macronutrient-matched control powder
Description: 50g macronutrient-matched powder that will lack strawberry flavonoids
Study: NCT02124304

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neck exercises using both manual and Thera-Band elasatic resistance
Description: Exercises will include cervical flexion and extension, and cervical right and left side-bending, and rotation. All 6 exercises will be done with both manual and elastic (Thera-Band) resistance.Manual Resistance is applied by the subject placing their own hand on their head and pushing in to it. Thera-Band bands will be used to provide elastic resistance
Study: NCT04126876

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline (0.9% sodium chloride)
Description: Intradermal, single injection of 1 ml plain saline (0.9% sodium chloride) at the primary melanoma excision site, one week prior to sentinel node biopsy (SNB).
Study: NCT01066624

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% Sodium Chloride irrigation solution
Description: Patients randomized to this group will be instructed to rinse their mouths twice, with 1 ounce (30 ml) of room temperature 0.9% NaCl (normal saline), 4 times daily after admission and until end of study

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cryotherapy (ice chips)
Description: Patients randomized to this group, on day -2 and -1, will be instructed to place approximately 1 ounce of crushed ice in their mouths 15 minutes prior to the initiation of melphalan infusion. The ice will be allowed to melt and should be replenish as soon as it had completely melted. Patients will be instructed to continue this procedure during the melphalan infusion and for 90 minutes after the end of the infusion.
Study: NCT01606774

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modernized prenatal care
Description: Home monitoring/phone surveillance/28 week ultrasound in place of 4-5 routine prenatal visits between 18 and 36 weeks
Study: NCT02114255

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of 0.9% NaCl.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG
Description: Vaccination with the live attenuated BCG vaccine.
Study: NCT00680797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Testosterone gel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Testosterone gel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estrogen
Description: Estrogen patch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estrogen
Description: Estrogen patch
Study: NCT03300921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Description: Product: Paricalcitol~Dose/Route/Regimen:~Arm A: 50mcg IV weekly Arm B: 12mcg PO daily